<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859569</url>
  </required_header>
  <id_info>
    <org_study_id>LY01011/CT-CHN-303</org_study_id>
    <nct_id>NCT04859569</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors</brief_title>
  <official_title>A Phase III Study Comparing Efficacy and Safety of LY01011 and Xgeva®(Denosumab) in Patients With Bone Metastases From Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luye Pharma Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luye Pharma Group Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter，randomized, double-blind, active-controlled, parallel-group study&#xD;
      comparing efficacy and safety of LY01011 (recombinant anti-RANKL human monoclonal antibody&#xD;
      injection) and Xgeva® in patients with bone metastases from solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate the similarity of clinical efficacy between LY01011 and&#xD;
      Xgeva® in patients with bone metastases from solid tumors.&#xD;
&#xD;
      The secondary objective is to evaluate the similarity of clinical safety and immunogenicity&#xD;
      between LY01011 and Xgeva® in patients with bone metastases from solid tumors.&#xD;
&#xD;
      Each subject will participate in the study for 53 weeks. Treatments are administered on day 1&#xD;
      and Q4W thereafter through week 49. All patients are instructed to take 500 mg calcium and&#xD;
      400 IU vitamin D daily.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Natural logarithm change from baseline to week 13 in uNTx/uCr</measure>
    <time_frame>from baseline to week 13</time_frame>
    <description>Compare LY01011 and Xgeva® for natural logarithm change in bone turnover marker(BTM) -urinary type I collagen cross-linked N-telopeptides (uNTx) corrected for urine creatinine(uCr) in chinese subjects with bone metastases from solid tumors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to first on-study skeletal-related event(SRE)</measure>
    <time_frame>from baseline to week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SRE</measure>
    <time_frame>from baseline to week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in bone specific alkaline phosphatase (s-BALP) from baseline to weeks 13, 25, and 53.</measure>
    <time_frame>from baseline to weeks 13, 25, and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Natural logarithm change in bone turnover marker-uNTx/uCr from baseline to weeks 25 and 53.</measure>
    <time_frame>from baseline to weeks 25 and 53</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">850</enrollment>
  <condition>Bone Metastases From Solid Tumors</condition>
  <arm_group>
    <arm_group_label>LY01011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of LY01011 120 mg (1.7ml) every 4 weeks for a maximum of 13 consecutive doses up to week 49.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xgeva®+LY01011</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After subcutaneous injection of Xgeva® 120 mg (1.7ml) every 4 weeks 3 times, patients of Xgeva® group continue to receive LY01011 120 mg (1.7ml) every 4 weeks for ten doses consecutively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY01011</intervention_name>
    <description>subcutaneously (SC) once every 4 weeks (Q4W)</description>
    <arm_group_label>LY01011</arm_group_label>
    <arm_group_label>Xgeva®+LY01011</arm_group_label>
    <other_name>recombinant anti-RANKL human monoclonal antibody injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xgeva®</intervention_name>
    <description>subcutaneously (SC) once every 4 weeks (Q4W)</description>
    <arm_group_label>Xgeva®+LY01011</arm_group_label>
    <other_name>Denosumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject or his/her guardian and/or impartial witness voluntarily signed the&#xD;
             written informed consent form（ICF）.&#xD;
&#xD;
          -  Aged 18 to 80 Years old (Female or male subjects to the date of signing the informed&#xD;
             consent form).&#xD;
&#xD;
          -  Subjects with solid tumor confirmed by histological or cytological examination. At&#xD;
             least one documented bone metastasis confirmed by computed tomography[CT], magnetic&#xD;
             resonance imaging[MRI]) or pathology (bone biopsy).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group（ECOG）performance status≤2.&#xD;
&#xD;
          -  Adequate organ function at baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with denosumab or other RANKL-targeted therapeutic drugs.&#xD;
&#xD;
          -  Subjects who previously received any bone-modifying agents (including intravenous or&#xD;
             oral bisphosphonates, etc.) for advanced tumor disease.&#xD;
&#xD;
          -  Orthopedic surgery or bone-related radiation therapy within 1 month prior to first&#xD;
             dose. Bone radioisotope therapy within 6 months prior to first dose, or planned&#xD;
             radiation therapy or surgery for bone during the study.&#xD;
&#xD;
          -  Past or ongoing osteomyelitis or osteonecrosis of the jaws （ONJ）, an active dental or&#xD;
             jaw condition requiring oral surgery, non-healed dental or oral surgery, or any&#xD;
             planned invasive dental procedure during the study period.&#xD;
&#xD;
          -  Primary central nervous system malignancy. Subjects with central nervous system&#xD;
             metastases who have failed local therapy. Subjects with asymptomatic brain metastases&#xD;
             or clinically stable brain metastases who do not require steroids and other therapy&#xD;
             for brain metastases for ≥ 28 days may be enrolled.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hu</last_name>
    <phone>021-64175590</phone>
    <email>xchu2009@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangdong Pharmaceutical University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xicheng Wang, master</last_name>
      <phone>13902400598</phone>
      <email>13902400598@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

